RT Journal Article
T1 Statin Therapy in Very Old Patients: Lights and Shadows
A1 Cobos-Palacios, Lidia
A1 Sanz-Cánovas, Jaime
A1 Muñoz-Ubeda, Mónica
A1 Lopez-Carmona, María Dolores
A1 Perez-Belmonte, Luis Miguel
A1 Lopez-Sampalo, Almudena
A1 Gómez-Huelgas, Ricardo
A1 Bernal-Lopez, Maria Rosa
K1 Statins
K1 Elderly
K1 Cardiovascular prevention
K1 Frailty
K1 Review
K1 Secondary prevention
K1 Atherosclerotic cardiovascular diseases
K1 Hypercholesterolemia
K1 Polypharmacy
K1 Primary prevention
K1 Cholesterol
K1 Morbidity
K1 Inhibidores de hidroximetilglutaril-CoA reductasas
K1 Anciano
K1 Enfermedades cardiovasculares
K1 Fragilidad
K1 Revisión
K1 Prevención secundaria
K1 Hipercolesterolemia
K1 Polifarmacia
K1 Prevención primaria
K1 Colesterol
K1 Morbilidad
AB Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death worldwide. High levels of total cholesterol-and of low-density lipoprotein cholesterol in particular-are one of the main risk factors associated with ASCVD. Statins are first-line treatment for hypercholesterolemia and have been proven to reduce major vascular events in adults with and without underlying ASCVD. Findings in the literature show that statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged people, but their benefits in older adults are not as well-established, especially in primary prevention. Furthermore, many particularities must be considered regarding their use in old subjects, such as age-related changes in pharmacokinetics and pharmacodynamics, comorbidities, polypharmacy, and frailty, which decrease the safety and efficacy of statins in this population. Myopathy and a possible higher risk of falling along with cognitive decline are classic concerns for physicians when considering statin use in the very old. Additionally, some studies suggest that the relative risk for coronary events and cardiovascular mortality associated with high levels of cholesterol decreases after age 70, making the role of statins unclear. On the other hand, ASCVD are one of the most important causes of disability in old subjects, so cardiovascular prevention is of particular interest in this population in order to preserve functional status. This review aims to gather the current available evidence on the efficacy and safety of statin use in very old patients in both primary and secondary prevention.
PB Frontiers
YR 2021
FD 2021-11-29
LK http://hdl.handle.net/10668/4262
UL http://hdl.handle.net/10668/4262
LA en
NO Cobos-Palacios L, Sanz-Cánovas J, Muñoz-Ubeda M, Lopez-Carmona MD, Perez-Belmonte LM, Lopez-Sampalo A, et al. Statin Therapy in Very Old Patients: Lights and Shadows. Front Cardiovasc Med. 2021 Nov 29;8:779044.
DS RISalud
RD Apr 8, 2025